GRB2 and non-small cell lung carcinoma: More importantly, from the observation in this map, GRB2 can activate the downstream pathways–Raf/MEK/ERK signaling pathway through ErbB signaling pathway and PI3K-Akt signaling pathway, which may make GRB2 one of the potential therapeutic targets for fucosterol in the treatment of NSCLC.